Teva Pharmaceutical Industries EBITDA 2010-2024 | TEVA

Teva Pharmaceutical Industries EBITDA for the quarter ending June 30, 2024 was $0.253B, a 171.47% decline year-over-year.

  • Teva Pharmaceutical Industries 2023 EBITDA was 1.586B, a 278.4% decline from 2022.
  • Teva Pharmaceutical Industries 2022 EBITDA was -0.889B, a 129.2% decline from 2021.
  • Teva Pharmaceutical Industries 2021 EBITDA was 3.045B, a 251.19% decline from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Teva Pharmaceutical Industries EBITDA 2010-2024 | TEVA

  • Teva Pharmaceutical Industries 2023 EBITDA was 1.586B, a 278.4% decline from 2022.
  • Teva Pharmaceutical Industries 2022 EBITDA was -0.889B, a 129.2% decline from 2021.
  • Teva Pharmaceutical Industries 2021 EBITDA was 3.045B, a 251.19% decline from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Dr Reddy's Laboratories (RDY)$13.1B
BridgeBio Pharma (BBIO)$5B
Bausch Health Cos (BHC)$3B
Amphastar Pharmaceuticals (AMPH)$2.4B
Supernus Pharmaceuticals (SUPN)$1.8B
Taysha Gene Therapies (TSHA)$449M
Personalis (PSNL)$315M
Assembly Biosciences (ASMB)$117M
Acasti Pharma (ACST)$28M
Sol-Gel Technologies (SLGL)$20M
Evoke Pharma (EVOK)$4M
Teligent (TLGT)$0M